Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Akero Therapeutics, Inc. (AKRO) filed a Form 4 reporting that Senior Vice President, Commercial Strategy Patrick Lamy sold 875 common shares on 06/20/2025 at $54.59 per share. The sale was made under the company’s automatic “sell-to-cover” policy to satisfy tax-withholding obligations that arose when restricted stock units vested, and therefore was not discretionary. After the transaction, Lamy continues to own 31,698 shares directly. No derivative securities were involved, and no other insider transactions were disclosed.
Akero Therapeutics Chief Scientific Officer Timothy Rolph executed a non-discretionary sale of 1,129 shares of common stock on June 18, 2025 at a weighted average price of $54.84 per share.
Key details of the transaction:
- The sale was conducted under a "sell-to-cover" policy to satisfy tax withholding obligations related to vesting restricted stock units
- Transaction prices ranged from $54.33 to $54.84 per share
- Following the transaction, Rolph directly owns 166,234 shares
- The sale was automatic and not at the discretion of the reporting person
This Form 4 filing indicates a routine insider transaction for tax purposes rather than a discretionary sale, suggesting no significant change in the insider's investment outlook.
Insider Trading Activity Report: William Richard White, Chief Financial Officer of Akero Therapeutics (NASDAQ: AKRO), reported a sale of 1,634 shares on June 18, 2025, at a weighted average price of $54.84 per share.
This transaction was executed as part of a "sell-to-cover" arrangement to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). The sales were automatic and not discretionary, conducted at prices ranging from $54.33 to $54.84 per share.
Following the transaction, White retains beneficial ownership of 57,521 shares held directly. The sale represents a routine tax-related transaction rather than a strategic investment decision by the insider.
Akero Therapeutics, Inc. (AKRO) – Form 4 insider transaction
Chief Development Officer Catriona Yale reported a single non-derivative transaction on 18 June 2025. The filing shows the automatic sale of 1,633 common shares at a weighted-average price of $54.84 (individual trades ranged from $54.33 to $54.84). The transaction was coded “S” and was executed under the company’s sell-to-cover policy to satisfy tax-withholding obligations arising from the vesting of restricted stock units. According to the footnotes, the sales were automatic and not at the officer’s discretion.
Following the transaction Ms. Yale continues to own 90,598 common shares directly. No derivative security activity was reported in Table II, and no additional transactions were disclosed.
The filing is a routine Section 16 disclosure; no earnings data, options exercises, or new awards were included.
Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), reported insider trading activity on June 18, 2025. The transaction involved the sale of 1,453 shares at a weighted average price of $54.84 per share as part of a "sell-to-cover" arrangement to satisfy tax withholding obligations related to vesting restricted stock units.
Following the transaction, Young directly owns 196,594 shares and indirectly holds beneficial ownership of additional shares through three irrevocable trusts:
- 20,000 shares in EA Irrevocable Trust
- 20,000 shares in CM Irrevocable Trust
- 20,000 shares in JL Irrevocable Trust
The trusts are managed by Young's spouse for their children's benefit, with Young disclaiming beneficial ownership of these trust-held securities. The reported sale was automatic and executed according to the company's tax withholding policy, not at Young's discretion.
Insider Trading Activity Report: Catriona Yale, Chief Development Officer of Akero Therapeutics (NASDAQ: AKRO), executed multiple transactions on June 16, 2025, as part of a pre-established Rule 10b5-1 trading plan from May 24, 2024.
Transaction Details:
- Exercised 10,000 stock options at $21.10 per share
- Subsequently sold a total of 10,000 shares in three tranches: - 6,210 shares at avg. price $53.78 - 2,895 shares at avg. price $54.80 - 895 shares at avg. price $55.52
- Following these transactions, Yale holds 92,231 shares directly
The transactions resulted in a reduction of Yale's holdings from 102,231 to 92,231 shares. The exercise and sale pattern suggests a typical insider stock option monetization strategy, with the sales prices representing a significant premium over the option exercise price.
Insider Trading Activity Report for Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics (AKRO), filed on June 28, 2025, detailing transactions executed on June 16, 2025 under a pre-established Rule 10b5-1 trading plan.
Key Transaction Details:
- Exercised 2,000 stock options at $19.87 per share
- Subsequently sold 2,000 shares in two tranches: - 1,500 shares at weighted average price of $53.82 - 500 shares at weighted average price of $55.09
- Post-transaction holdings: 32,573 shares held directly and 64,182 remaining stock options
The stock options were granted with a 48-month vesting schedule starting December 8, 2023, with expiration in December 2033. All transactions were executed according to a Rule 10b5-1 trading plan established on January 6, 2025, demonstrating planned and compliant insider trading practices.